Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Joint Damage Prediction in Non-Severe Hemophilia A with Artificial Intelligence.

Journal of blood medicine·2026
Same author

Thrombomodulin resistance as a novel prothrombotic pathway in COVID-19.

Scientific reports·2025
Same author

Management of Thrombosis in a Patient with Three Thrombophilic Disorders.

Journal of blood medicine·2024
Same author

Antithrombin Deficiency and Thrombosis: A Wide Clinical Scenario Reported in a Single Institution.

Journal of blood medicine·2023
Same author

Thrombotic Antiphospholipid Syndrome and Direct Oral Anticoagulants: Unmet Needs and Review of the Literature.

Seminars in thrombosis and hemostasis·2023
Same author

Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: A systematic review and meta-analysis.

Tropical medicine & international health : TM & IH·2023

Related Experiment Video

Updated: Nov 17, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K

Autoimmune Acquired Factor XIII Deficiency: A Case Report.

Ana Marco1,2, Pascual Marco1,2,3

  • 1Thrombosis and Hemostasis Department, Hematology Service, University General Hospital in Alicante, Alicante, Spain.

Journal of Blood Medicine
|February 19, 2021
PubMed
Summary

Autoimmune acquired factor XIII deficiency, a rare bleeding disorder, can cause severe hematomas. Early diagnosis and immunosuppression are key to managing this condition and preventing potentially fatal outcomes.

Keywords:
acquired diseaseautoantibodiesfactor XIII deficiencyhematomaspontaneous

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.9K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K

Related Experiment Videos

Last Updated: Nov 17, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.2K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.9K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.5K

Area of Science:

  • Hematology
  • Immunology

Background:

  • Autoimmune acquired factor XIII (FXIII) deficiency is a rare bleeding disorder.
  • Characterized by severe spontaneous hematomas and autoantibodies against FXIII, it has high mortality rates.

Observation:

  • A 70-year-old patient presented with recurrent muscular hematomas.
  • Initial hemostasis and platelet studies were normal, excluding common bleeding disorders.
  • Factor XIII levels were critically low (<10%), indicating deficiency.

Findings:

  • Acquired FXIII deficiency was confirmed through normal FXIII gene sequencing and absence of personal/family bleeding history.
  • Plasma autoantibodies against FXIII were detected, confirming an autoimmune etiology.
  • Treatment with immunosuppression and hemostatic agents led to symptom resolution.

Implications:

  • This case highlights the importance of considering acquired FXIII deficiency in patients with unexplained bleeding.
  • Prompt diagnosis and management, including immunosuppression, are crucial for improving patient outcomes.
  • The persistent low-level inhibitor suggests the need for long-term monitoring in acquired FXIII deficiency.